RYTM Filings — Rhythm Pharmaceuticals, Inc. - FilingSpy
RYTM
Rhythm Pharmaceuticals, Inc.
A biopharmaceutical company that makes medicines for rare genetic diseases of severe obesity, marked by insatiable hunger and excess weight gain. Its marketed drug, IMCIVREE (setmelanotide), is a precision medicine that restores a signaling pathway in the brain controlling hunger and fullness for patients with conditions such as Bardet-Biedl syndrome and POMC deficiency. Founded in 2008 in Boston, the company's name echoes the body's internal rhythm of hunger and metabolism its medicines aim to reset.
German Christopher PaulCorporate Controller & CAO · 25 transactions
—
1.9K
20.3K
—
19.0K
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.15M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.